3 January 2023
Medannex CEO Ian Abercrombie was interviewed for the latest edition of Pharma Intelligence’s global pharmaceutical publication ‘Scrip’, released last week.
The article highlights the recent progress that has accelerated Medannex to its current clinical stage.
It also discusses the first-in-human study (Phase Ib, oncology) with MDX-124 – the first therapy to target annexin-A1 – and how Medannex plans to develop the monoclonal antibody as a new treatment option in various disease areas.
Key quotes from the article include:
“(Annexin-A1) is a novel target that has not been explored in any therapeutic context to date. It helps modulate the immune system and plays a key role in the development of cancers and autoimmune diseases, along with many other conditions.”
“(Mr Abercrombie believes) that MDX-124 will be on the market within five years in either a paediatric cancer or pancreatic cancer indication”.
Read the full article here: https://scrip.pharmaintelligence.informa.com/SC147590/Medannex-Advances-First-ANAX1-Antagonist-With-Modular-Cancer-Trial-Approach